GSK3B and myotonic dystrophy type 1: Some further studies performed in young HSALR mice have reported that chemical inhibition of glycogen synthase kinase 3 beta (GSK3β) corrects impaired Celf1 activity, thus preventing the development of DM1 muscle pathology, including muscle atrophy21.